CStone Pharmaceuticals (HKG:2616)
Hong Kong · Delayed Price · Currency is HKD 5.04
-0.05 (-0.88%)
Oct 21, 2026, 4:08 PM HKT
CStone Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2025
-
CS2009’s Phase I update reported 30.9% grade 3+ treatment-related adverse events and 71.4% overall disease control, with encouraging post-IO NSCLC activity. Phase II is underway, with 20 vs. 30 mg/kg dose selection and NSCLC development planned.
Fiscal Year 2023
Fiscal Year 2020
-
Pfizer’s $200m investment and China commercialization rights for sugemalimab anchor a broader oncology collaboration, including co-development and joint in-licensing. A first-line stage IV NSCLC NDA was targeted before year-end 2020, with other major indication data and launches advancing.